1398P - Clinico-pathological characteristics and treatment outcome of young breast cancer patients: an institutional study

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Breast Cancer
Cancers in Adolescents and Young Adults (AYA)
Presenter Vinod Raina
Authors V. Raina1, A. Gogia2, S.V.S. Deo3, B.K. Mohanti4, N.K. Shukla3
  • 1Dept. Of Medical Oncology & Haematology & Stem Cell Transplant, All India Institute of Medical Sciences (AIIMS)Institute Rotary Cancer Hospital, IN-110029 - New Delhi/IN
  • 2Medical Oncology, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN
  • 3Surgical Oncology, AIIMS, 110029 - New Delhi/IN
  • 4Radiation Oncology, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN



Breast cancer in young women (<35 years) is uncommon and accounts for 1-2 % of all breast cancer in the West. There is a paucity of data on young breast cancer from India. The aim of our study was to assess clinical, pathological parameters and outcome in young breast cancer patients.


This analysis was carried out in 250 patients aged 35 years or less, who were registered in our clinic between 2000-2011 at I.R.C.H, A.I.I.M.S. This constituted about 7.5% of all new cases. Patients' records were analyzed from computer database using ICD code (C-50).


The median age was 31 years (range 18-35). The median duration of symptoms was 10 (range 0.25-60). Breast lump was the commonest (93%) presenting symptom (left >right side). Ninety percent of patients were married and median age at first child birth was 23 years. Positive family history was elicited in 10 patients. Five patients presented with synchronous malignancy. The TNM (7th edition) stage distribution was stage I - 2.5 %, stage II - 30%, stage III - 46.5%, and stage IV - 22%. The median clinical tumor size was 5.0 cm. Modified radical mastectomy was the commonest surgical procedure and this was done in 83 % of cases. The histopathological analysis showed 94% had infiltrating ductal carcinoma. Thirty percent of tumors were high grade and 70% had pathological node-positive disease. ER/PR and Her2neu positivity was 33% and 29%, respectively. Triple-negative breast cancer (TNBC) constituted 31%. A combination of anthracyclines and taxanes were used in the majority of patients and trastuzumab was used only in 3 % of cases. With a median follow up of 28 months (non-metastatic group), 3-year disease-free survival (DFS) and overall survival (OS) was 50% and 60%. Higher Nodal stage, tumor size (>5 cm), negative hormonal status (triple negative) and visceral metastasis at baseline predicted poor outcome.


Young women constituted 7.5 % of breast cancer cases. The proportion of triple negative (nearly one third) was also higher than the Western population. Higher stage and triple negative status results in poorer outcome.


All authors have declared no conflicts of interest.